Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review.

Background: This single-center, retrospective study evaluated the effects of de-escalating cystic fibrosis (CF) supportive therapies in patients on elexacaftor/tezacaftor/ivacaftor (ETI). For many with CF, the clinical benefit of ETI exceeds that of supportive therapies. Therefore, we anticipated patients would desire to discontinue many of their supportive therapies, leading to the creation of a de-escalation algorithm.

Evaluation of a remote hybrid staffing model for ambulatory clinical pharmacists in a pediatric health system during the COVID-19 pandemic.

Purpose: To describe and quantify patient care activities performed by ambulatory clinical pharmacists supporting medical specialty clinics in a pediatric health system utilizing a hybrid staffing model during the coronavirus disease 2019 (COVID-19) pandemic.

Methods: Five ambulatory clinical pharmacists, integrated within a health-system specialty pharmacy (HSSP), utilized a web-based data collection tool to record time spent performing patient care activities over a 2-week period. Work location (onsite or offsite) of the pharmacist was reported for each activity.

Interacting drivers and their tradeoffs for predicting denitrification potential across a strong urban to rural gradient within heterogeneous landscapes.

Denitrification is a significant regulator of nitrogen pollution in diverse landscapes but is difficult to quantify. We examined relationships between denitrification potential and soil and landscape properties to develop a model that predicts denitrification potential at a landscape level. Denitrification potential, ancillary soil variables, and physical landscape attributes were measured at study sites within urban, suburban, and forested environments in the Gwynns Falls watershed in Baltimore, Maryland in a series of studies between 1998 and 2014.

Practitioner Due Diligence: Real-World Lumacaftor/Ivacaftor Use.

Objective: Previous trials evaluated the efficacy of lumacaftor/ivacaftor in Phe508del homozygotes. These trials are limited by manufacturer sponsorship and were conducted under strict protocol. Additionally, this therapy is costly and does not allow for reduction in daily cystic fibrosis therapies.